Muutke küpsiste eelistusi

Endothelial Dysfunctions in Vascular Disease [Kõva köide]

Edited by , Edited by
  • Formaat: Hardback, 432 pages, kõrgus x laius x paksus: 259x185x26 mm, kaal: 1132 g, 40 illustrations
  • Ilmumisaeg: 15-Mar-2007
  • Kirjastus: Wiley-Blackwell (an imprint of John Wiley & Sons Ltd)
  • ISBN-10: 1405122080
  • ISBN-13: 9781405122085
Teised raamatud teemal:
  • Kõva köide
  • Hind: 131,49 €*
  • * saadame teile pakkumise kasutatud raamatule, mille hind võib erineda kodulehel olevast hinnast
  • See raamat on trükist otsas, kuid me saadame teile pakkumise kasutatud raamatule.
  • Kogus:
  • Lisa ostukorvi
  • Tasuta tarne
  • Lisa soovinimekirja
  • Raamatukogudele
  • Formaat: Hardback, 432 pages, kõrgus x laius x paksus: 259x185x26 mm, kaal: 1132 g, 40 illustrations
  • Ilmumisaeg: 15-Mar-2007
  • Kirjastus: Wiley-Blackwell (an imprint of John Wiley & Sons Ltd)
  • ISBN-10: 1405122080
  • ISBN-13: 9781405122085
Teised raamatud teemal:
In an effort to produce more and better clinical applications, including earlier diagnostic tests, more targeting therapies and means of prevention, the contributors of these 26 articles describe their current research in such topics as the basis of endothelial involvement in vascular disease, the endothelium and cardiovascular risk factors, diagnostic tools and markers of endothelial functions, and endothelium-related prevention and therapy. Specific topics include function and dysfunction, endothelial activation and the initiation of atherosclerosis, high-density lipoprotein and atheroprotection, infections and vascular disease, endothelial vasodilatory dysfunction in early life, vascular function and diabetes mellitus, treatment by cholesterol, and stem cell research. Annotation ©2007 Book News, Inc., Portland, OR (booknews.com)

Bridging the gap between the laboratory and the bedside, this timely volume illuminates the connection between endothelial dysfunction and vascular disease. This comprehensive survey of atherosclerotic disease begins with biology – incorporating the latest breakthroughs in the field – then elucidates risk factors and diagnostic tools and markers. A major section on endothelium-directed prevention and therapy shows you how to apply cutting-edge research to clinical care.

Under the careful editorial guidance of Drs. De Caterina and Libby, the highly-regarded contributors address:
- endothelial activation and the initiation of atherosclerosis
- mechanisms of plaque progression and complications
- the role of LDL in the origin and progression of atherosclerosis
- advanced glycation endproducts and the accelerated atherosclerosis in diabetes
- oxidative stress and vascular disease
- soluble adhesion molecules as markers of vascular disease
- hormone-replacement therapy and cardiovascular risk
- anti-oxidants and endothelial protection
and more.

The first book dedicated to the central role of endothelial dysfunction in vascular disease, this concise volume gathers all the latest information on the subject into one convenient and cohesive text. Make sure your patients are benefiting from current knowledge by keeping a copy of Enothelial Dysfunctions in Vascular Disease close at hand for frequent consultation.

Introduction
Every book has a history, this one not excepted, having emerged from intersections in professional lives of the Editors. This book bears the fruits of a collaboration between the “pupil” (RDC) and the “mentor” (PL). During an extended sabbatical of the pupil in Boston in 1994, we probed together the concept that endothelial dysfunction served as a common denominator of vascular disease, with the balance between inflammation and its inhibition as a fulcrum of the regulation of the behavior of endothelial cells. As practicing cardiologists in our clinical lives, we sought to link to endothelial function the mechanisms of action of risk factors and of pharmacologic agents used to treat and prevent vascular disease. The pupil therefore authored a few reviews on the mechanism of action of risk factors and included them in a small book, published in Italian, for which the mentor wrote a preface. The book was greeted with favor from the Italian cardiological community, and provided the nidus for the present, more ambitious endeavor, which includes updated reviews on the pathogenesis of vascular disease and on the most novel aspects of vascular biology. This enterprise was enabled by the contributions of many of our former or present collaborators and colleagues, without whose enthusiasm and engagement this work could never have seen light. We largely underestimated the devotion necessary on our own side at the beginning, but it ultimately yielded a product that we feel achieves our original goals. We are aware that we confront a continuously evolving topic, where frequent updates would be desirable - if not necessary. Yet, we believe in the value of books - such as the current one - that attempt to organize in a snapshot of time, the vast amount of literature available in a coherent and comprehensive scheme. We are aware of existing gaps, of emerging material not paid its due, and of the rapid evolution of some of the concepts highlighted within. The links between the laboratory and the clinic have never afforded more opportunity for new understanding and advances in diagnosis and treatment than today We hope that our colleagues, vascular biologists cardiologists, internists, and other physicians alike will find this compendium a useful guide to this most exciting time in vascular biology and medicine


Raffaele De Caterina and Peter Libby

Contributors vii
Preface x
Foreword xi
Michael A. Gimbrone Jr.
Acknowledgments xiii
Dedication xiv
Part I The basis of endothelial involvement in vascular diseases
1(84)
Endothelial functions and dysfunctions
3(23)
Raffaele De Caterina
Marika Massaro
Peter Libby
Endothelial activation and the initiation of atherosclerosis
26(10)
Raffaele De Caterina
Antonella Zampolli
Guido Lazzerini
Peter Libby
Mechanisms of plaque progression and complications
36(19)
Raffaele De Caterina
Antonella Zampolli
Serena Del Turco
Peter Libby
Angiogenesis in cardiovascular disease
55(30)
Karen S. Moulton
Part II The endothelium and cardiovascular risk factors
85(92)
VLDL and atherosclerosis
87(8)
Jan Nilsson
Mikko P.S. Ares
Wolfgang Dichtl
High-density lipoprotein and atheroprotection
95(13)
Brian Krause
Reynold Homan
Roger Newton
Advanced glycation endproducts and the accelerated atherosclerosis in diabetes
108(21)
Giuseppina Basta
Ann Marie Schmidt
Raffaele De Caterina
Homocysteine and endothelial dysfunction
129(11)
Rosalinda Madonna
Raffaele De Caterina
Lipoprotein(a) and the artery wall
140(8)
Angelo M. Scanu
Marilena Formato
Oxidative stress and vascular disease
148(17)
Dominik Behrendt
Peter Ganz
Infections and vascular disease
165(12)
Amir Kol
Peter Libby
Part III Diagnostic tools and markers of endothelial functions
177(96)
Endothelial vasodilatory dysfunction: basic concepts and practical implementation
179(10)
Scott Kinlay
Peter Ganz
Endothelial vasodilatory dysfunction and risk factors in adults
189(10)
Mark R. Adams
David S. Celermajer
Endothelial vasodilatory dysfunction in early life
199(14)
Julian P.J. Halcox
John E. Deanfield
Endothelial vasodilatory dysfunction in hypertension
213(19)
Umberto Campia
Julio A. Panza
Vascular function and diabetes mellitus
232(13)
Mark A. Creager
Joshua A. Beckman
Dyslipidemia and endothelial dysfunction: pathophysiology and therapy
245(13)
Todd J. Anderson
Francois Charbonneau
Soluble adhesion molecules as in vivo biohumoral markers of vascular cell activation
258(15)
Jacopo Gianetti
Raffaele De Caterina
Part IV Endothelium-directed prevention and therapy
273(128)
Hormone replacement therapy and cardiovascular disease
275(11)
Tommaso Simoncini
Anti-atherogenic effects of omega-3 fatty acids
286(14)
Antonella Zampolli
Erling Falk
Raffaele De Caterina
Treatment of endothelial dysfunction and atherosclerosis by cholesterol lowering
300(15)
Masanori Aikawa
Peter Libby
Antioxidants and endothelial protection
315(8)
Domenico Pratico
Angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers to reverse endothelial dysfunction
323(14)
G.B. John Mancini
Sammy Y. Chan
PPARs in atherosclerosis
337(13)
Ouliana Ziouzenkova
Nikolaus Marx
Peter Libby
Jorge Plutzky
Stem cells in atherosclerosis and atherosclerosis-related vascular disorders
350(15)
Yong-Jian Geng
Rosalinda Madonna
Endothelium-targeted gene and cell-based therapy for cardiovascular disease
365(36)
Luis G. Melo
Alok S. Pachori
Deling Kong
Massimiliano Gnecchi
Victor J. Dzau
Index 401


Raffaele De Caterina, MD. Director, Laboratory for Thrombosis and Vascular Research, CNR Institute of Clinical Physiology, Pisa Dr. Peter Libby, MD. Chief, Cardiovascular Medicine, Brigham and Women's Hospital. Mallinckrodt Professor of Medicine, Harvard Medical School